Polygalacic acid attenuates cognitive impairment by regulating inflammation through PPARγ / NF‐κB signaling pathway
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14581 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Tan Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Cen…. Hauptthemen laut MEDLINE: NF-kappa B, Cognitive Dysfunction, Saponins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Scientific Instrument and Equipment Development Projects of China, Beijing Scholars Program, Beijing Brain Initiative from Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
Aims
We aimed to explore the role and molecular mechanism of polygalacic acid (PA) extracted from traditional Chinese medicine Polygala tenuifolia in the treatment of Alzheimer's disease (AD).
Methods
The network pharmacology analysis was used to predict the potential targets and pathways of PA. Molecular docking was applied to analyze the combination between PA and core targets. Aβ42 oligomer‐induced AD mice model and microglia were used to detect the effect of PA on the release of pro‐inflammatory mediators and its further mechanism. In addition, a co‐culture system of microglia and neuronal cells was constructed to assess the effect of PA on activating microglia‐mediated neuronal apoptosis.
Results
We predict that PA might regulate inflammation by targeting PPARγ‐mediated pathways by using network pharmacology. In vivo study, PA could attenuate cognitive deficits and inhibit the expression levels of inflammation‐related factors. In vitro study, PA can also decrease the production of activated microglia‐mediated inflammatory cytokines and reduce the apoptosis of N2a neuronal cells. PPARγ inhibitor GW9662 inversed the neuroprotective effect of PA. Both in vivo and in vitro studies showed PA might attenuate the inflammation through the PPARγ/NF‐κB pathway.
Conclusions
PA is expected to provide a valuable candidate for new drug development for AD in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.
- Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, China.
- Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, China.
- Center of Alzheimer's Disease, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, China.
- Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China.
ORCID-Profile: Tan Zhao
Förderung
- National Key Scientific Instrument and Equipment Development Projects of China
- Beijing Scholars Program
- Beijing Brain Initiative from Beijing Municipal Science and Technology Commission
- Key Project of the National Natural Science Foundation of China
Zitieren
APA
Zhao, T., & Jia, J. (2024). Polygalacic acid attenuates cognitive impairment by regulating inflammation through PPARγ / NF‐κB signaling pathway. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14581
Vancouver
Zhao T, Jia J. Polygalacic acid attenuates cognitive impairment by regulating inflammation through PPARγ / NF‐κB signaling pathway. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14581
BibTeX
@article{Zhao2024,
author = {Zhao, Tan and Jia, Jianping},
title = {Polygalacic acid attenuates cognitive impairment by regulating inflammation through PPARγ / NF‐κB signaling pathway},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14581}
}
EUVIMED